CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea · Delayed Price · Currency is KRW 3,685.00
+80.00 (2.22%)
At close: Oct 26, 2026
CJ Bioscience Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,677 | 3,693 | 3,467 | 5,575 | 4,075 | 4,363 |
Revenue Growth | 8.72% | 6.52% | -37.82% | 36.82% | -6.61% | -17.86% |
Gross Profit Gross Profit Growth | 718.04 | 632.96 | 284.83 | 1,773 | 1,311 | 1,642 |
Operating Income Operating Income Growth | -22,977 | -24,786 | -34,241 | -32,057 | -33,233 | -10,108 |
Net Income Net Income Growth | -22,327 | -24,005 | -32,838 | -22,913 | -34,913 | -19,272 |
Earnings Per Share EPS Growth | -1708.88 | -1837.29 | -3541.00 | -3235.00 | -5940.02 | -4533.00 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
South Korea South Korea Growth | 3,344 | 3,246 | 3,002 | 4,152 | 3,440 | 4,089 |
Overseas Overseas Growth | 332.65 | 446.61 | 464.75 | 529.21 | 410.02 | 273.93 |
Total Total Growth | 3,677 | 3,693 | 3,467 | 4,681 | 3,850 | 4,363 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 40,951 | 50,839 | 75,309 | 64,095 | 49,324 | 80,080 |
Total Debt Total Debt Growth | 7,882 | 10,411 | 9,351 | 8,533 | 28,966 | 23,891 |
Net Cash (Debt) Net Cash Growth | 33,069 | 40,427 | 65,958 | 55,562 | 20,357 | 56,190 |
Net Cash Growth | -37.61% | -38.71% | 18.71% | 172.93% | -63.77% | 1501.15% |
Net Cash Per Share Net Cash Per Share Growth | 2531.04 | 3094.21 | 7111.76 | 7843.75 | 3463.50 | 13214.21 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -19,768 | -23,416 | -27,760 | -24,899 | -20,963 | -8,437 |
Capital Expenditures CapEx Growth | -19.76 | -10.66 | -377.59 | -4,924 | -4,145 | -952.65 |
Free Cash Flow Free Cash Flow Growth | -19,788 | -23,427 | -28,138 | -29,823 | -25,108 | -9,390 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 19.53% | 17.14% | 8.22% | 31.80% | 32.19% | 37.62% |
Operating Margin | -624.86% | -671.24% | -987.76% | -575.00% | -815.61% | -231.68% |
Pretax Margin | -607.20% | -650.10% | -947.28% | -410.99% | -856.84% | -441.72% |
Profit Margin | -607.20% | -650.10% | -947.28% | -410.99% | -856.84% | -441.72% |
FCF Margin | -538.13% | -634.44% | -811.70% | -534.93% | -616.19% | -215.22% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 12.81 | 32.98 | 38.03 | 26.38 | 41.84 | 65.56 |